Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$16.00 USD
-0.60 (-3.61%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $16.00 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 16.00 -0.60(-3.61%)
Will DNLI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
Other News for DNLI
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Denali Therapeutics price target lowered by $38 at UBS, here's why
Denali Therapeutics files to sell 29.29M shares of common stock for holders
Denali Therapeutics files to sell 29.29M shares of common stock for holders